Methylated Tumor-Specific DNA as a Plasma Biomarker in Patients with Glioma

Weaver, Kyle D.; Grossman, Stuart A.; Herman, James G.

doi:10.1080/07357900500449546

Cited by 74 publications

(45 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Techniques such as methyl-BEAMing, methylation-specific PCR, and quantum dot–based fluorescence resonance energy transfer (QD-FRET) have been adapted to detect methylated fragments of DNA extracted from plasma. 78,84–86 Much like measuring mutations in ctDNA, methylated DNA fragments from the tumor found in circulation are similar to the degree of methylation in the tumor itself and may also correspond to tumor burden. The overall specificity of measuring methylated DNA is lower as compared with genomic alterations, potentially because of the fact that there are often overlapping methylation changes in the tumor and surrounding normal tissue.…”

Section: Epigenetic Changesmentioning

confidence: 99%

Liquid Biopsies: Genotyping Circulating Tumor DNA

Díaz

Bardelli

2014

JCO

1,899

1,571

View full text Add to dashboard Cite

Genotyping tumor tissue in search of somatic genetic alterations for actionable information has become routine practice in clinical oncology. Although these sequence alterations are highly informative, sampling tumor tissue has significant inherent limitations; tumor tissue is a single snapshot in time, is subject to selection bias resulting from tumor heterogeneity, and can be difficult to obtain. Cell-free fragments of DNA are shed into the bloodstream by cells undergoing apoptosis or necrosis, and the load of circulating cell-free DNA (cfDNA) correlates with tumor staging and prognosis. Moreover, recent advances in the sensitivity and accuracy of DNA analysis have allowed for genotyping of cfDNA for somatic genomic alterations found in tumors. The ability to detect and quantify tumor mutations has proven effective in tracking tumor dynamics in real time as well as serving as a liquid biopsy that can be used for a variety of clinical and investigational applications not previously possible.

show abstract

Section: Epigenetic Changesmentioning

confidence: 99%

Liquid Biopsies: Genotyping Circulating Tumor DNA

Díaz

Bardelli

2014

JCO

1,899

1,571

View full text Add to dashboard Cite

show abstract

“…This biomarker may be useful as a source of patient stratification for clinical trials. MGMT status can be identified in tissue and serum from GBM patients [89,90]. …”

Section: Potential Glioma Biomarker Candidatesmentioning

confidence: 99%

Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science

Hochberg

Atai

Gonda

et al. 2014

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

Glioma is the most common brain tumor. For the more aggressive form, glioblastoma, standard treatment includes surgical resection, irradiation with adjuvant temozolomide and, on recurrence, experimental chemotherapy. However, the survival of patients remains poor. There is a critical need for minimally invasive biomarkers for diagnosis and as measures of response to therapeutic interventions. Glioma shed extracellular vesicles (EVs), which invade the surrounding tissue and circulate within both the cerebrospinal fluid and the systemic circulation. These tumor-derived EVs and their content serve as an attractive source of biomarkers. In this review, we discuss the current state of the art of biomarkers for glioma with emphasis on their EV derivation.

show abstract

“…This epigenetic approach has been used in various cancers such as non-small cell lung cancer,70 head and neck cancers,71 colon cancer72 and glioma73 to develop cancer markers based on promoter hypermethylation. In non-invasive prenatal diagnosis, previous studies have shown that DNA methylation in placental tissues (the major source of fetal DNA in maternal plasma)74 and maternal blood cells (the presumed major source of maternal DNA in maternal plasma)75 are different in many genomic regions 76 – 79.…”

Section: Interpretation Of Negative Results With Confidencementioning

confidence: 99%

Detection of circulating fetal nucleic acids: a review of methods and applications

Hung

Chiu

2009

J Clin Pathol

View full text Add to dashboard Cite

The discovery of cell-free circulating fetal nucleic acids in maternal plasma has opened up new possibilities in non-invasive prenatal diagnosis. The rapid advancement of this field in the past decade is catalysed by the discovery of new classes of fetal nucleic acid markers and technological developments in nucleic acid detection and amplification. In this review, some of the more significant recent developments in this field will be discussed, including the detection of single molecule, chromosomal aneuploidies, single nucleotide variations and placental microRNAs in maternal plasma.

show abstract

Methylated Tumor-Specific DNA as a Plasma Biomarker in Patients with Glioma

Cited by 74 publications

References 22 publications

Liquid Biopsies: Genotyping Circulating Tumor DNA

Liquid Biopsies: Genotyping Circulating Tumor DNA

Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science

Detection of circulating fetal nucleic acids: a review of methods and applications

Contact Info

Product

Resources

About